The board of directors of Eli Lilly (LLY) and Company approved a new $15B share repurchase program. The company’s prior $5B share repurchase ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
In the U.S., the chorus of opposition against the proposed merger continues to grow and now includes the CEOs of Roche and ...
Eli Lilly will launch Mounjaro in India in 2025. The drug treats type 2 diabetes and obesity. Lilly received marketing ...
Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.